Opinion|Videos|August 23, 2024
Biosimilar Utilization and Inventory Management
Author(s)Sophia Humphreys, PharmD, MHA
Sophia Humphreys, PharmD, MHA, BCBBS, discusses biosimilar utilization and inventory management.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- How has the introduction of biosimilars affected the biologic landscape at specialty pharmacies, including the disease states treated and trends in utilization?
- What strategies, including the “just in time” inventory model, can specialty pharmacies employ to effectively manage their high-cost biologic and biosimilar inventory given the challenges of limited shelf space?
Advertisement
Related to this article
BRUIN CLL-313 showed significantly longer progression-free survival vs bendamustine plus rituximab, bringing a noncovalent BTK inhibitor to first-line care.
A behavioral walking program matched supervised aerobic training for improving asthma control in a randomized trial of physically inactive adults.
Phase 2b data from EASD 2026 show the amylin-incretin combination also cut HbA1c by up to 2.9% in adults with obesity or overweight and type 2 diabetes.
American Pharmacists Month kicked off on October 1, honoring more than 700,000 pharmacy professionals and 250 years of caring for America's communities.
fMRI data show cagrilintide-semaglutide altered brain responses to high-calorie food cues; REIMAGINE analyses point to ectopic fat and bone effects.
Decades after cisplatin's approval, platinum-based chemotherapy continues to anchor treatment regimens across tumor types, new research finds.
A pharmacist-led collaborative drug therapy management program at NYC Health + Hospitals/Bellevue reported high patient satisfaction, and every surveyed patient said they felt respected and supported by their pharmacist.
A Novo Nordisk–funded claims analysis of adults with type 2 diabetes found an adjusted HR of 1.06 for MACE with switching, although the findings cannot show causation.
Advertisement
Advertisement